Ipca Laboratories LimitedQ1 FY27 Results & Financial Update
Ipca Laboratories Limited: Q1 FY27 consolidated results and company financials – revenue ₹2,788.10 Cr, PAT ₹424.27 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Ipca Laboratories price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Ipca Laboratories Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Ipca Laboratories recorded consolidated revenue from operations of Rs 2,788.10 crores for the first quarter ended June 30, 2026, compared to Rs 2,308.85 crores in the corresponding period of the previous year, with management reporting a top-line expansion of 21% in official disclosures.
Consolidated total income for Q1 FY27 reached Rs 2,813.36 crores, up 20% from Rs 2,341.51 crores reported in Q1 FY26, supported by steady growth across both formulations and API verticals.
Profitability expanded significantly during the quarter, with consolidated profit before tax (PBT) rising to Rs 572.08 crores from Rs 330.51 crores, and profit after tax (PAT) before non-controlling interest reaching Rs 424.81 crores compared to Rs 234.42 crores in Q1 FY26.
Profit for the period attributable to the owners of the company was reported at Rs 401.89 crores, delivering basic and diluted earnings per share of Rs 15.84 for the quarter compared to Rs 9.19 per share in the year-ago period.
Operating performance received a notable boost from favorable currency movements, with forex gains of Rs 31.57 crores recorded during the quarter compared to a forex loss of Rs 8.16 crores in Q1 FY26.
Finance costs reduced by 36% to Rs 11.88 crores from Rs 18.51 crores in the corresponding quarter last year, reflecting improved capital efficiency and debt servicing.
Tax expenses for Q1 FY27 stood at Rs 149.27 crores, reflecting higher taxable profits across the consolidated entity compared to Rs 96.09 crores in Q1 FY26.
During the quarter, the Board of Directors resolved at its meeting held on June 26, 2026, to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with Ipca Laboratories, with an appointed date of April 1, 2026, subject to necessary statutory consents and approvals.
01 · Business model
What does Ipca Laboratories do?
Ipca Laboratories Limited is a fully integrated Indian pharmaceutical company with a strong international footprint, specializing in the manufacture and marketing of both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).
The company's commercial operations span domestic formulations, international branded and institutional formulations, export generics, and active pharmaceutical ingredients, supported by extensive manufacturing infrastructure.
Ipca operates within a single primary business segment, Pharmaceuticals, through its holding company, various domestic and international subsidiaries, step-down subsidiaries, associates, and joint ventures.
02 · Historical context
What shaped the business before this quarter
In October 2025, Unichem Laboratories completed the sale of freehold land and building at Prabhat Estate, Mumbai, to Lodha Developers for an agreed consideration of Rs 279 crores, generating a net consolidated gain of Rs 17.65 crores.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹2,788.10 Cr |
| Total income | ₹2,813.36 Cr |
| Profit before tax | ₹572.08 Cr |
| Profit after tax | ₹424.27 Cr |
| EPS | ₹15.84 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 15.2% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 20.5% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹25.26 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Total formulations revenue reached Rs 1,685.16 crores in Q1 FY27 compared to Rs 1,410.62 crores in Q1 FY26, representing a 19% increase led by robust institutional and domestic performance.
Domestic formulations income grew 13% to reach Rs 1,082.12 crores during the quarter, up from Rs 961.01 crores in Q1 FY26.
Export formulations grew across categories, with institutional formulations surging 107% to Rs 119.75 crores, branded export formulations rising 16% to Rs 143.27 crores, and export generics expanding 27% to Rs 340.02 crores.
Total API revenue grew 30% to Rs 423.72 crores in Q1 FY27 from Rs 326.34 crores in Q1 FY26, with domestic APIs up 20% to Rs 91.37 crores and export APIs up 33% to Rs 332.35 crores.
Revenue from operations contributed by subsidiaries stood at Rs 668.86 crores for Q1 FY27 compared to Rs 561.95 crores in Q1 FY26, reflecting a 19% increase.
What drove margins
Consolidated EBITDA before forex gain/loss and other income reached Rs 637.94 crores in Q1 FY27, representing an EBITDA margin of 22.88% compared to 18.39% in Q1 FY26.
Cost of materials consumed was Rs 638.14 crores alongside purchases of stock-in-trade of Rs 140.69 crores, offset by a positive inventory change of Rs 18.52 crores.
Employee benefits expense stood at Rs 601.56 crores for the quarter, while other expenses were recorded at Rs 719.68 crores.
Depreciation and amortization expense rose 11% to Rs 110.81 crores, while finance costs declined by 36% to Rs 11.88 crores.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
In accordance with Ind AS 108, the group's operations are categorized in a single operating segment, namely Pharmaceuticals.
Geography and market mix
Q1 FY27 revenue from India stood at Rs 1,229.21 crores (compared to Rs 1,083.17 crores in Q1 FY26), while revenue from outside India reached Rs 1,558.89 crores (compared to Rs 1,225.68 crores in Q1 FY26).
The geographic information of non-current assets held outside India accounts for less than 10% of the total non-current assets of the group and is not disclosed separately.
06 · Reported developments
What changed operationally
Consolidated revenue from operations grew 21% year-over-year to Rs 2,788.10 crores, and net profit attributable to owners rose 72% to Rs 401.89 crores.
Statutory auditors N V C & Associates LLP issued an unmodified review report on both standalone and consolidated unaudited financial results for Q1 FY27.
07 · Beyond the numbers
What changed beyond the numbers
Reported update
Subsidiary Inventory Accounting Harmonization
Statutory auditors noted that one subsidiary prepared special purpose consolidated financial results with inventory valuation cost formula changed from weighted average to First-In, First-Out (FIFO) to harmonize with the parent company's accounting policy.
08 · Key Q&A
The quarter, answered directly
What does Ipca Laboratories do?
Ipca Laboratories Limited is a fully integrated Indian pharmaceutical company with a strong international footprint, specializing in the manufacture and marketing of both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).
What is the clearest takeaway from Q1 FY27?
Ipca Laboratories recorded consolidated revenue from operations of Rs 2,788.10 crores for the first quarter ended June 30, 2026, compared to Rs 2,308.85 crores in the corresponding period of the previous year, with management reporting a top-line expansion of 21% in official disclosures.
What drove revenue or demand?
Total formulations revenue reached Rs 1,685.16 crores in Q1 FY27 compared to Rs 1,410.62 crores in Q1 FY26, representing a 19% increase led by robust institutional and domestic performance.
What mattered most for margins or profitability?
Consolidated EBITDA before forex gain/loss and other income reached Rs 637.94 crores in Q1 FY27, representing an EBITDA margin of 22.88% compared to 18.39% in Q1 FY26.
What changed operationally beyond the headline numbers?
Statutory auditors noted that one subsidiary prepared special purpose consolidated financial results with inventory valuation cost formula changed from weighted average to First-In, First-Out (FIFO) to harmonize with the parent company's accounting policy.
What should the next disclosure help confirm?
Track regulatory and shareholder approvals regarding the proposed amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories.
09 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
10 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Statutory Approvals for Amalgamation: Track regulatory and shareholder approvals regarding the proposed amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.